MRI Announces Strong Initial Phase 1 Data for ARR-217 ADC ESMO
ArriVent BioPharma released initial encouraging Phase 1 data for the ARR-217 ADC showing a 44.8% ORR at 6mg/kg in colorectal cancer patients, generally well-tolerated, and sent the stock higher post-debut.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed